Navigation Links
Medisafe 1 Technologies Announces Delay in Closing $7MM Perpetual License Sale Due to Hurricane Sandy
Date:11/5/2012

JERUSALEM, November 5, 2012 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the final pages which includes the review of the licensed contract by both parties for the closing of a $7MM non-exclusive perpetual license sale agreement have been postponed due to Hurricane Sandy.  The sale is currently on track to be completed on or around November 15.

As previously reported, the agreement will transfer rights for the full commercialization, marketing and distribution of its patented medicinal locking mechanism and bar-code matching system to a third party.  Terms of the sale include a one-time $7MM payment to Medisafe 1 Technologies.  

"Medisafe 1 Technologies looks forward to completing the sale and achieving a major milestone for our company in the coming days," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle.  Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties i
'/>"/>

SOURCE Medisafe 1 Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medisafe 1 Technologies Anticipates a Special Dividend of $0.01 (One Cent) to Each Shareholder of One Common Stock pending the $7MM Perpetual License Sale of Technology Rights
2. Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
3. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
4. Life Technologies Acquires Advanced Microscopy Group
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
7. Life Technologies Collaborates with USDA to Develop Same-Day, Multi-Strain E. coli Detection System
8. LightPath Technologies Provides Quarterly Update on Infrared Initiatives
9. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz
10. Harvest Technologies Corporation reicht Patentverletzungsklage gegen ThermoGenesis Corporation ein
11. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015  Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to ... Chief Financial Officer, will present at the Jefferies 2015 Global ... in New York City . ... from the Cambrex website at www.cambrex.com in the ... be available for 90 days after the live event concludes.  ...
(Date:5/27/2015)... , May 27, 2015  Novartis will highlight ... 21 medicines and 11 investigational compounds across more ... Society of Clinical Oncology (ASCO) Annual Meeting, May ... Hematology Association (EHA), June 11-14. Data will demonstrate ... types, including melanoma, lung, breast, kidney and blood ...
(Date:5/27/2015)... , May 25, 2015 Research and Markets ... the "Research and Future Development Trend Forecast of ... At present, there are 35,600 dialysis centers ... ratio are large due to the different regional operating ... centers in other Asian countries are operated by state-owned ...
Breaking Medicine Technology:Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 2Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 3Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 4Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 5Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 6Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 7Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 8China Dialysis Market Report: Research and Future Development Trends and Forecasts 2015-2020 2
... and BRUSSELS, June 30, 2011 UCB and Harvard ... signing ceremony that took place in Boston last night ... of Belgium. (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) ... bridge between industry and academia, with Harvard scientists continuing ...
... 2011 Company remains committed to speeding ... R&D pipeline boasts 70 potential medicines in clinical development, including 33 ... least ten potential new medicines in Phase III by the end ... areas such as neuroscience, diabetes and oncology, as well as new ...
Cached Medicine Technology:UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16
(Date:5/27/2015)... 2015 CompanionDx announced that ... genomic analysis in personalized cancer therapy: Non-small cell lung ... Society of Clinical Oncology (ASCO) as part of their ... , The molecular and clinical data used for the ... database. The study reports improved patient outcomes from a ...
(Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
(Date:5/27/2015)... This is a professional and ... Omega-3 industry. The report provides a basic overview ... industry chain structure. The Omega-3 market analysis is ... competitive landscape analysis, and key regions development status. ... Company, Seadragon Marine Oils, Norwegian Fish Oil, Croda ...
(Date:5/27/2015)... Meadows, IL (PRWEB) May 27, 2015 ... release of its SonarMD Platform, a first-of-its ... monitoring and managing patients with chronic gastrointestinal ... Kosinski, MD, MBA, the application allows physicians ... visits through the ongoing use of electronic ...
(Date:5/27/2015)... “Heroin has never been more plentiful or ... coming from,” says Harford County Sheriff Jeff Gahler, as quoted ... the surging heroin related incidents in Baltimore, police resources are ... prevent heroin addiction and subsequent abuse before it turns into ... Baltimore is a drug and alcohol rehab facility specializing in ...
Breaking Medicine News(10 mins):Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3
... Service Provider Chooses SonicWALL to Satisfy Business Need ... SonicWALL, Inc. (Nasdaq: SNWL ... announced that ZirMed, Inc., a leader in revenue ... Louisville, Kentucky, has implemented a SonicWALL(R) E-Class NSA ...
... Clarient, Inc. (Nasdaq: CLRT ... resource for pathologists, oncologists and the pharmaceutical industry, today ... renewed, expanded and extended its senior subordinated revolving credit ... SFE ), Clarient,s majority shareholder."In the current market ...
... medical equipment supplier, now sells its DRE Integra AV-S with a ventilator ... patients attempt to breathe spontaneously. , ... (Vocus) March 3, 2009 -- ... by Business First of Louisville, continues expanding its DRE Integra AV-S ...
... releases the first in a series of residential vacuum cleaner reviews ... , ... Boise, Idaho (Vocus) March 3, 2009 -- Before spending hundreds of ... the market, savvy shoppers turn to the Internet to research their choices. ...
... incidence of obesity-induced type 2 diabetes mellitus continues to ... obesity can completely eliminate all manifestations of diabetes. In ... The American Journal of Medicine , investigators analyzed ... showed that 78.1% of diabetic patients had complete resolution ...
... that helps trigger autoimmunity could lead to new treatments ... kill thousands of children annually, according to researchers. , ... has discovered genetic evidence that two distinct molecular ... a vitally important cell type in limiting undesirable immune ...
Cached Medicine News:Health News:SonicWALL Delivers Flexible High-Performance Threat Management for ZirMed 2Health News:SonicWALL Delivers Flexible High-Performance Threat Management for ZirMed 3Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 2Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 3Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 4Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 2Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 3Health News:DRE AV-S Ventilator Now Has Multiple Spontaneous Breathing Modes 4Health News:Shopping for a Vacuum Cleaner? Know What You're Buying! Internet Site and Rating System Can Help 2Health News:Shopping for a Vacuum Cleaner? Know What You're Buying! Internet Site and Rating System Can Help 3Health News:Study shows potential for resolving type 2 diabetes with bariatric surgery 2Health News:Genetic evidence points to potential therapeutic bypass for autoimmune process 2Health News:Genetic evidence points to potential therapeutic bypass for autoimmune process 3
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
... Bard Collagen Implant, the world's leading bulking ... for the treatment of Stress Urinary Incontinence ... surrounding urethral tissue to aid coaptation in ... body's own structure, Contigen Bard Collagen Implant ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
... The AMS 650™ and 600M™ malleable ... many patientsespecially those with limited dexterity. These ... allows the patient to position them in ... make the penis rigid enough for sexual ...
Medicine Products: